Name | Butein |
Synonyms | Butein BUTEIN(P) Butein 2',3,4,4'-Tetrahydroxychalcone 2-[(E)-2-(2-aminophenyl)vinyl]-5-methyl-8-quinolinol 2-[(E)-2-(2-aminophenyl)vinyl]-5-methyl-quinolin-8-ol 2-[(E)-2-(2-aminophenyl)ethenyl]-5-methylquinolin-8-ol 2-[(E)-2-(2-aminophenyl)ethenyl]-5-methyl-quinolin-8-ol 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-, (2E)- (E)-1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one2',3,4,4'-Tetrahydroxychalcone |
CAS | 487-52-5 |
EINECS | 207-659-5 |
Molecular Formula | C15H12O5 |
Molar Mass | 272.25 |
Density | 1.483±0.06 g/cm3(Predicted) |
Melting Point | 216°C |
Boling Point | 560.9±50.0 °C(Predicted) |
Solubility | DMSO: >50mg/mL |
Appearance | solid |
Color | yellow |
pKa | 7.44±0.35(Predicted) |
Storage Condition | 2-8°C |
Sensitive | Sensitive to heat, light and air |
MDL | MFCD00017300 |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |
HS Code | 29145090 |
Reference Show more | 1. Liu Keyan, Duan Jialin, Su Jing, Tao Xingru, Zhao Shi, Baiyang, Wei Peifeng, Mao Miao. Protective effect of purple flower pigment on oxidative stress injury in PC12 cells and its effect on mitochondrial function [J]. China Pharmacy, 2020,31(24):2974-2981. 2. Kedi Liu et al. [IF = 3.24]. "Network pharmacology and molecular docking reveal the effective entities and active mechanisms of Dalbergia." Plos One. 2021 Sep;16(9):e0255736 3. [IF = 2.903] Pei Zhang et al."Effects of butein on human steosarcoma cell propagation, apotosis, and autosogagy through oxidative stress:." Humexp Toxicol. 2022;(): |
biological activity | Butein, available from Dalbergia dorifera T. Chen, isolated, is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μm for pde4. Butein is a protein tyrosine kinase inhibitor with IC50 of 16 and 65 μm for EGFR and p60c-src, respectively. Butein targets FoxO3a through AKT and ERK/p38 MAPK pathways to sensitize HeLa cells to Cisplatin. Butein is also a SIRT1 activator (STAC). |
Cell Line: | HeLa cells HeLa cells |
Concentration: | 10, 20, and 40 μM 20 µM |
Incubation Time: | 24, 48, and 72 hours 24 hours |
Result: | Inhibited cell growth in a dose- and time-dependent manner. Decreased phosphorylation of AKT, ERK and p38 co-treatment with Cisplatin (20 µM). Enhanced the antitumor effects of Cisplatin in vivo. |
Animal Model: | Nude mice (12 female 6- or 7-week old) with subcutaneous tumor xenografts |
Dosage: | 2 mg/kg |
Administration: | Intraperitoneally; every 2 days; for 3 weeks |
uses | Butrin, isobutin, and butein from medical plant Butea monospecerma selection: suppression of tumor necrosis factor-α, interleucin (IL)-6, and IL-8. |